ScienceDirect , The Journal of Clinical Endocrinology and Metabolism , vol
In June, Vivani said it received approval from an Australian human research ethics committee to begin SLIM-1, the first human clinical trial of its semaglutide implant
Mounjaro and Zepbound, Lillys weekly injectable drugs that target the incretins GIP and GLP-1, have put Lilly at the head of the white-hot obesity and diabetes space
The ISAAC study in which such a standardized methodology was applied found a high worldwide variation in the prevalence and severity of asthma, rhinitis and eczema
This is an important step forward :) Another brilliant meta analysis Ilaria Costantini - lovely work and really careful and thoughtful interpretations as always - great to see the involvement of those with lived experience and how it has actively shaped conclusions and recommendations - as with anything what might be good in the short term may go on to have later consequences ( ie., shift to restrictive eating or other maladaptive coping strategies for underlying anxiety) so I agree longer term follow ups important too
Trying to stretch this is a false economy
